It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, our integrated DMPK solutions combine in vitro and in vivo pharmacokinetics, bioanalysis, and biotransformation insights – enhanced through modeling and simulation – to deliver data that reduces risk and accelerates timelines. From hit identification to candidate nomination, we provide the clarity and confidence you need to make the right decisions at the right time.
Robust DMPK data is essential to every stage of drug discovery. We integrate advanced assays, predictive modeling, and translational strategies to ensure your program moves forward with confidence.
Our experts guide project teams, helping you anticipate challenges and act quickly to maximize scientific impact.
Formulation challenges such as poor solubility or polymorphic transitions can derail early discovery. We address these proactively, improving PK reliability and reducing viable candidates. Species-specific formulations enhance preclinical relevance, and early collaboration between DMPK and formulation scientists delivers measurable benefits in candidate selection and downstream development.
Our DMPK Solutions
We provide end-to-end DMPK support, tailored to the evolving needs of each phase from early discovery through clinical candidate nomination. Our adaptive approach ensures data relevance, informed decision-making, and alignment of your objectives.
Lipophilicity and solubility are more than numbers; they’re predictors of success. By combining advanced methodologies with expert interpretation, Sygnature Discovery helps you optimize drug design strategies, reduce risk, and move confidently toward clinical milestones.
At Sygnature Discovery, we help you understand how your compound will behave in the body by assessing chemical and metabolic stability early in development. Our expertise accelerates optimization, improves pharmacokinetic predictions, and strengthens translational accuracy.
Advanced tissue binding assays that reveal how drugs behave in the body. By focusing on unbound drug, the fraction that truly drives therapeutic effect, we deliver insights that improve pharmacokinetic predictions, guide dosing strategies, and accelerate candidate optimization.
Drug-drug interactions (DDIs) can compromise safety, efficacy, and regulatory success. At Sygnature Discovery, we combine validated in vitro assays with expert interpretation to reduce risk and accelerate your path to the clinic.
Advanced biotransformation solutions that help you optimize compounds and make confident decisions faster. Our scientists combine deep expertise with cutting-edge analytical platforms to provide high-resolution data that drives success from hit identification through preclinical candidate selection.
Sensitive, reproducible LC-MS/MS methods tailored to diverse compound classes and biological matrices. From early discovery through non-GLP preclinical studies, we provide accurate quantification of parent compounds, metabolites, and biomarkers, helping your move from insight to outcome faster.
in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies designed to deliver high-quality, decision-enabling data. Combined with quantitative bioanalysis utilizing UPLC-MS/MS platforms with rigorous method development tailored to diverse analytes assessed against predefined acceptance criteria aligned with current bioanalytical guidelines delivers high-quality, reproducible data that supports confident decision-making and accelerates progression through the drug development pipeline.
Make confident translational decisions with integrated PK and PK/PD modelling that connects high-quality in vitro and in vivo data to predictive simulations. We help you optimize dose selection, refine study design, and anticipate human exposure-response early reducing attrition and accelerating progression from hit-to-lead through IND-enabling studies and beyond.
Effective integration of DMPK science is essential to the rational progression of compounds through the drug discovery pipeline. DMPK insights clarify ADME properties, guide medicinal chemistry optimization, and support prediction of human pharmacokinetics. Rigorous evaluation of in vitro and in vivo data enables early identification of liabilities, strengths translational modelling, and improves the selection of compounds with optimal developability. By embedding DMPK strategy throughout discovery, teams can mitigate risk, refine compound design, and accelerate the advancement of high-quality candidates toward clinical development.
Integrated DMPK strategies enable predictive insights, reduce development risk, improve PK reliability, accelerate timelines, enhance translational relevance, and support informed decision-making from early discovery to candidate nomination.
Integrated science & technology
Seamless data flow across DMPK, solid form, formulation and wider drug discovery.
Accelerated decision making
Informed, phase-appropriate strategies that reduce risk and timelines.
Tailored Collaboration
Bespoke study design, adaptable business models and transparent communication.
Tailored Collaboration
Recognizing the unique demands of each program, we prioritize flexibility in study design and execution. From early ADME screening to advanced formulation technologies, our teams tailor approaches to deliver phase-relevant, decision-enabling data. Our DMPK scientists provide expert support across in vitro ADME assays, bioanalysis, PK/PD interpretation, and predictive modelling, ensuring scientific rigor and translational value throughout the discovery pipeline.
Integrated Expertise Across Discovery
Embedding DMPK within a broader discovery framework enables fully integrated support across formulation, biology, pharmacology, and chemistry. Whether it’s early screening, enabling formulations, or strategies for complex programs, our multidisciplinary teams deliver tailored insight and operational excellence to maximize translational impact.
Why Choose Sygnature Discovery for DMPK Support?
We offer flexible, collaborative DMPK support tailored to your program’s needs. Our scientists deliver phase-appropriate strategies that reduce risk, accelerate timelines, and solve complex pharmacokinetic and metabolism challenges from early screening to predicting effective clinical doses. With seamless data integration across disciplines, and transparent business models, we ensure responsive, expert-driven support throughout your project.
Meet our Team
The experts behind smarter DMPK decisions. From hit identification to candidate nomination, they deliver clarity through integrated in vitro and in vivo insights.
Bifunctional degraders bind and degrade proteins via ubiquitin ligase, despite breaking bRo5 rules. Translating in vitro DMPK data to in vivo performance remains a challenge. At Sygnature Discovery, we provide tailored assays and expertise to support projects involving these compounds. Read more in the poster.
Posters
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
